Moderate

Interstitial lung disease — diagnostic approach (MDT)

DPLD work-up · Respiratory
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Diffuse parenchymal lung disease encompasses hundreds of entities; accurate classification drives prognosis and treatment. A multidisciplinary approach integrating clinical, radiological and (where needed) pathological data is the diagnostic gold standard.

Red flags

  • Rapid progression / acute exacerbation
  • Resting hypoxaemia at presentation
  • Features of connective-tissue disease or vasculitis
  • Honeycombing with declining FVC

Assessment

Differential diagnosis

  • Idiopathic pulmonary fibrosis (UIP)
  • Connective-tissue-disease ILD
  • Hypersensitivity pneumonitis
  • Sarcoidosis
  • Drug-induced ILD
  • Occupational/pneumoconiosis
  • Organising pneumonia

Investigations

  • Detailed history: exposures, drugs, occupation, connective-tissue symptoms, family history
  • HRCT chest with inspiratory/expiratory and prone sequences
  • Full lung function: spirometry, lung volumes, DLCO, walk test with oximetry
  • Autoimmune panel (ANA, ENA, RF, anti-CCP, myositis panel, ANCA)
  • Precipitins / specific IgG for HP antigens
  • BAL and/or lung cryobiopsy/surgical biopsy when diagnosis remains uncertain
  • Echocardiogram for pulmonary hypertension screen

Management

  • Take a comprehensive exposure, drug, occupational and autoimmune history
  • Examine for clubbing, crackles, extrapulmonary (skin, joint, muscle) signs
  • Obtain a high-quality HRCT and define the pattern (UIP, NSIP, OP, HP)
  • Characterise physiology with full lung function and desaturation on exertion
  • Send a targeted serological panel to detect occult connective-tissue disease
  • Reserve BAL and biopsy for cases where imaging/clinical data are insufficient
  • Bring all data to an ILD multidisciplinary meeting for consensus diagnosis
  • Assign a working diagnosis and define the progressive-fibrosing risk
  • Decide therapy: immunosuppression for inflammatory, antifibrotics for progressive fibrosis
  • Set up longitudinal monitoring, supportive care and transplant consideration

Drugs & doses

No empirical therapy before MDT diagnosis; treatment is diagnosis-specific
Oxygen as needed for exertional/resting hypoxaemia
Vaccination (influenza, pneumococcal, COVID-19) as supportive care

Disposition

ILD specialist centre with MDT; early transplant referral for progressive disease.

Complications & pitfalls

  • Misclassification leading to wrong treatment
  • Progression to respiratory failure
  • Pulmonary hypertension
  • Biopsy-related acute exacerbation

Exam pearls

  • A confident multidisciplinary diagnosis outperforms any single test
  • Myositis-specific antibodies (e.g. anti-MDA5, anti-Jo1) explain many 'idiopathic' ILDs
  • Prone HRCT distinguishes dependent atelectasis from true early fibrosis
  • Treat the progressive fibrosing phenotype even when the underlying label is uncertain

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.